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See Article, pages 163–169The ﬁrst potent and speciﬁc inhibitor of the NS3/4A
serine protease to be tested in a randomized, placebo-
controlled pilot study in patients with chronic hepatitis
C was ciluprevir (BILN 2061). In previously untreated
patients with genotype 1 infection, treatment with cilu-
previr for 2 days resulted in HCV RNA reductions of
2–3 log10 copies/mL in most of the patients, thus provid-
ing proof-of-concept that HCV NS3/4A protease inhib-
itors are a therapeutic option for patients with chronic
hepatitis C [1]. However, further clinical development
of ciluprevir was suspended following reports of cardio-
toxicity in animal studies [1].
The NS3/4A protease inhibitors telaprevir and boce-
previr have been shown to reduce serumHCVRNA levels
when used alone [2,3] and to produce additive reductions
in levels when administered with peginterferon (PEG-
IFN) [3,4]. Telaprevir monotherapy for 2 weeks was asso-
ciated with a more than 4 log10 median reduction of HCV
RNA in patients with chronic hepatitis C genotype 1
infection [2]. When used as monotherapy, current prote-
ase inhibitors show a low barrier to genetic resistance, a
potential problem for antivirals given the high rate and
error-prone nature of HCV replication [5].
The study by Lawitz et al. [6] in the current issue of
this Journal assessed the safety and antiviral eﬀects of
telaprevir (750 mg q8h) in combination with peginterfer-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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patients infected with HCV genotype 1 received triple
therapy for 28 days and could then start oﬀ-study treat-
ment with PEG-IFN alfa-2a and RBV for up to 44
weeks at the discretion of the investigator and patient.
All patients had undetectable HCV RNA levels by day
28, indicating that the addition of PEG-IFN and RBV
may be able to inhibit the rapid selection of resistant
strains as observed in the telaprevir monotherapy trials.
Eight patients completed 44 weeks of oﬀ-study standard
of care combination therapy. Eight patients achieved a
sustained virologic response, including one patient
who received only 22 weeks of treatment. In general, tri-
ple therapy was well tolerated, however, rash or pruritus
occurred in 5 of the 12 patients [6].
Based on these data, larger phase II clinical trials
have been initiated and very recently completed [7,8].
The PROVE 1 trial in the US enrolled patients into 4
treatment groups: (i) group 1: telaprevir 750 mg q8h,
with PEG-IFN and RBV for 12 weeks; (ii) groups 2
and 3: patients received the same triple combination
for 12 weeks, followed by treatment with PEG-IFN plus
RBV alone for 12 or 36 weeks, respectively; (iii) group 4:
48 weeks of PEG-IFN plus RBV (controls). The
PROVE 2 trial was conducted in Europe and had a sim-
ilar design as PROVE 1, with an extra arm evaluating
the PEG-IFN/telaprevir combination without RBV.
In PROVE 2 HCV RNA was undetectable at week 4
in 122 of 163 patients (75%) receiving triple therapy [8].
Thus, compared to the 12 patients of the study of Lawitz
et al. (100% RVR), the RVR in the PROVE 2 study was
apparently lower. Certainly, patients in the ﬁrst pilot
study of triple therapy were under very careful surveil-
lance. Compliance with drug doses and intervals mayPublished by Elsevier B.V. All rights reserved.
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PROVE studies. Other factors may comprise adverse
events leading to premature discontinuation, the devel-
opment of viral resistance and breakthrough, perhaps
due to diﬀerent PEG-IFN and/or RBV sensitivities in
the respective patient populations.
With the addition of direct antivirals to PEG-IFN/
RBV several questions must be addressed in the future:
(i) Will every HCV-1 infected patient need the addi-
tion of a protease inhibitor to improve changes
for SVR?
Probably not because patients with a low baseline
viral load and a rapid virologic response comprising
approximately 15% of the overall HCV-1 infected popu-
lation already have SVR rates around 90% with only 24
weeks of PEG-IFN and RBV combination therapy [9].
(ii) What is the minimum Peg-IFN and RBV sensitiv-
ity to avoid functional monotherapy?
An ‘‘ideal” direct antiviral drug or drug combination
which does not select for resistant strains may not
require combination with PEG-IFN and RBV. How-
ever, drugs with a low genetic barrier such as protease
inhibitors currently require the combination with
PEG-IFN and RBV to eradicate the mutant viral
strains. Whether substantial reduction of HCV RNA
replication can restore innate immunity and IFN sensi-
tivity in vivo (as it has been shown in vitro [10]) remains
to be proven. Such eﬀects would most likely enhance
SVR rates.
(iii) Is RBV needed? Is PEG-IFN needed?
The RBV sparing arm of PROVE 2 clearly shows
that RBV is required in particular to reduce virologic
relapse rates after the end of therapy. Furthermore, pre-
liminary data from the SPRINT1 trial [11] suggest that
RBV doses cannot even be reduced to 400–800 mg with-
out reducing the chances to achieve a virologic response.
The question whether (peg)interferon is ultimately
required cannot be answered at present. However,
proof-of-concept pilot trials using potent protease and
polymerase inhibitors in combination with RBV may
provide an answer in the near future.
(iv) Is there a potential value of a PEG-IFN/RBV
lead-in phase?
Hypothetically, achieving steady-state levels for
peginterferon and ribavirin may (quantitatively) reduce
the selection and expansion of resistant strains after
the addition of a protease inhibitor. However, virologic
response rates 12 weeks after the end of therapy inpatients treated for 24–28 weeks with peginterferon
alfa-2b, ribavirin and boceprevir were similar but inde-
pendent of a 4-week lead-in phase with PEG-IFN/
RBV (57% vs. 55%) [11]. The beneﬁt of a lead-in phase
remains to identify patients who do not require the addi-
tion of a protease inhibitor (low baseline viral load and
RVR) and those who do not respond at all to PEG-
IFN/RBV and would be exposed to functional mono-
therapy by addition of a protease inhibitor.
(v) How long must a potent direct antiviral be given
and how long should be the overall treatment
duration?
Direct antiviral agents may eradicate the sensitive
wild-type population rapidly, perhaps within 8–12
weeks, which is reﬂected in the design of forthcoming
phase III trial with telaprevir. So far, in patients with
virologic breakthrough or relapse treated with telaprevir
only resistant but not wild-type variants were identiﬁed
supporting the concept that approximately 8–12 weeks
may suﬃce to eradicate the sensitive viral population.
The question of how long PEG-IFN/RBV therapy must
be continued to eradicate the mutant variants is quite
unclear. Data suggest that overall PEG-IFN/RBV
should be continued longer in patients not achieving a
RVR (e.g. 36 vs. 12 additional weeks). On the other
hand, in PROVE 2 62% and 68% of HCV-1 infected
patients achieved an SVR with 12-week triple therapy
and 12-week triple therapy followed by another 12
weeks of PEG-IFN/RBV combination, respectively.
This implies that more than 90% of patients achieving
an SVR in the latter group were apparently overtreated.
The crucial question how patients who require more
than 12-week triple therapy can be identiﬁed will need
further attention. Possibly, pretreatment and on-treat-
ment predictors of SVR may diﬀer with triple therapy
compared to PEG-IFN/RBV standard combination
therapy.
(vi) How important is the pharmacokinetic proﬁle of
an antiviral drug?
Several HCV NS3/4A protease inhibitors are cur-
rently dosed every 8 h. Experience from the treatment
of HIV shows that compliance and adherence to such
dosing intervals is impaired and aﬀects antiviral
responses. A major diﬀerence between HIV and HCV,
however, is the overall duration of combination therapy.
Patients should be able to adhere to strict dosing inter-
vals for a limited period of time better than if treatment
is required indeﬁnitely. Nevertheless, there is no doubt
that antiviral drugs which require only once (qd) or
twice (bid) a day dosing will be preferred. Pharmacoki-
netics may also aﬀect the emergence of resistant strains.
So far, little information is published and more com-
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and the emergence of resistant strains are required.
(vii) Will the improvement in SVR rates be the only
parameter to consider?
In the past, progress in the treatment of chronic hep-
atitis C was deﬁned by improvement of SVR rates.
Patients who failed PEG-IFN and RBV treatment were
generally not considered to have endured any harm
beyond the side eﬀects they suﬀered during therapy.
However, in the era of drugs rapidly selecting for resis-
tance, the question needs to be answered, whether
selected HCV strains in non-responders will persist
and impair the chances for patients to be cured in the
future with the development of antiviral combination
therapies of, e.g., protease and polymerase inhibitors.
Data for how long resistant strains can persist and
whether these mutants can improve viral ﬁtness by com-
pensatory mutations are largely lacking.
(viii) What are the short and long-term side eﬀects of the
new direct antiviral drugs?
Relevant clinical and laboratory side eﬀects of protease
inhibitors comprise rash (telaprevir), anemia (telaprevir,
boceprevir) and gastrointestinal side eﬀects. Cardiotoxic-
ity – as described for ciluprevir in monkeys – has yet not
been observed in clinical trials in patients with chronic
hepatitis C. All adverse events so far described were fully
reversible after drug discontinuation. The safety data
base, however, is still too small to deﬁnitely exclude the
risk of life-threatening or irreversible side eﬀects.
The data of the study by Lawitz et al. [6] as well as the
recently presented data for telaprevir from the PROVE
studies [7,8] clearly show the tremendous potential of
new direct antiviral drugs. Many patients are desperately
waiting for improved treatment modalities for chronic
hepatitis C.Representatives from the industry developing
these new compounds together with those from academic
centers performing phase 1–3 clinical trials and regula-
tory agencies must carefully balance the urgent need for
these new drugs on one hand with the responsibilities
and requirements of a thoughtful and comprehensive
clinical development program on the other hand [12] that
should answer most of the questions raised above.References
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